Sugi Predict

Sugi Predict / Compounds / SCHEMBL2907756

SCHEMBL2907756

SCHEMBL2907756

CC1CC(c2ccc(C(N)=O)c(C3=CCCCC3)c2)CC(C)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 15/20 0.38
▸ KIT P10721 6/20 0.36
▸ CYP2C19 P33261 2/20 0.36
▸ GRM2 Q14416 1/20 0.35
▸ ACMSD Q8TDX5 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ BMPR1B O00238 1/20 0.34
▸ PLK4 O00444 1/20 0.34
▸ STK25 O00506 1/20 0.34
▸ RIOK3 O14730 1/20 0.34
▸ CHEK1 O14757 1/20 0.34
▸ GAK O14976 1/20 0.34
▸ DCLK1 O15075 1/20 0.34
▸ MUSK O15146 1/20 0.34
▸ EPHB6 O15197 1/20 0.34
▸ PDPK1 O15530 1/20 0.34
▸ MAP3K13 O43283 1/20 0.34
▸ DAPK3 O43293 1/20 0.34
▸ MAP3K7 O43318 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907755 1.00 CSF1R (0.38) CSF1RKITCYP2C19GRM2ACMSD
SCHEMBL2912758 1.00 CSF1R (0.38) CSF1RKITCYP2C19GRM2ACMSD
SCHEMBL4318977 0.82 CSF1R (0.52) CSF1RKITCYP2C19GRM2ACMSD
SCHEMBL2907303 0.82 CSF1R (0.52) CSF1RKITCYP2C19HDAC1HDAC2
SCHEMBL4189037 0.82 CSF1R (0.52) CSF1RKITCYP2C19GRM2ACMSD
SCHEMBL3164533 0.81 CSF1R (0.51) CSF1RKITCYP2C19HDAC1HDAC2
SCHEMBL4182550 0.81 CSF1R (0.52) CSF1RKITCYP2C19GRM2ACMSD
SCHEMBL4181684 0.80 CSF1R (0.54) CSF1RKITCYP2C19GRM2NTRK1
SCHEMBL4183531 0.80 CSF1R (0.53) CSF1RKITCYP2C19GRM2HDAC1
SCHEMBL4347924 0.79 CSF1R (0.36) CSF1RKITCYP2C19GRM2ACMSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662837-B2 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-16 — — US claimed
US-7645755-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICAL N.V. (BE) 2010-01-12 — — US claimed
EP-1951234-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-06 — — EP claimed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 — — EP claimed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 — — WO claimed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 — — US claimed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 — — US claimed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 — — WO claimed
US-10806737-B2 Compounds and methods for the targeted degradation of fetal liver kinase polypeptides ARVINAS OPERATIONS, INC. (US) 2020-10-20 — — US disclosed
EP-3559006-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES Arvinas Operations, Inc. (US) 2019-10-30 — — EP disclosed
US-20180256586-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES ARVINAS OPERATIONS, INC. 2018-09-13 — — US disclosed
WO-2018118598-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES Arvinas, Inc. (US) 2018-06-28 — — WO disclosed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 — — US disclosed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 — — EP disclosed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 — — WO disclosed
WO-2006138155-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-28 — — WO disclosed
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 — — US disclosed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 — — US disclosed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 — — US disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES CSF1R 34/4885KIT 125/4885CYP2C19 3150/4885
US-20180256586-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES MDM2, CRBN, FLT3 CSF1R 806/4885KIT 557/4885CYP2C19 4600/4885
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR FLT3, MCL1, CSF1R CSF1R 3/4885KIT 70/4885CYP2C19 2318/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES CSF1R 34/4885KIT 125/4885CYP2C19 3150/4885
US-10806737-B2 Compounds and methods for the targeted degradation of fetal liver kinase polypeptides MDM2, CRBN, FLT3 CSF1R 806/4885KIT 557/4885CYP2C19 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.